Pharmaceuticals
with passion
Corporate

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%)[1], Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets.

Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2025. Its results reflect a year of strategic evolution and solid performance of key brands – all contributing to market share growth.

Read more
Corporate

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

GSK plc (LSE/NYSE: GSK) and Alfasigma S.p.A. today announced a licence agreement under which Alfasigma will acquire worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).

Read more
All news

Therapeutic areas

Gastroenterology

Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)

Vascular

Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions

Rheumatology

We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis

Metabolic

In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles

Nutraceuticals & Medical foods

With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue

CSR

Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.

Read more
×

You’re entering Alfasigma global website

I agree